플러스100%마이너스

  • 화면크기
통합검색

한의약융합데이터센터


근거중심한의약 DB

Home > 한의약융합데이터센터 > 근거중심한의약 DB
Title

Ω 3 fatty acids may reduce hyperlipidemia in pediatric renal transplant recipients.

Authors

Filler G, Weiglein G, Gharib MT, Casier S.

Journal

Pediatr Transplant.

Year

2012

Vol (Issue)

16(8)

Page

835-9.

doi

10.1111/j.1399-3046.2012.01772.x.

PMID

22835217

Url

http://www.ncbi.nlm.nih.gov/pubmed/22835217

MeSH

Adolescent
Calcineurin/antagonists & inhibitors
Child
Cholesterol/blood
Diet
Fatty Acids, Omega-3/metabolism*
Female
Humans
Hyperlipidemias/prevention & control*
Hyperlipidemias/therapy*
Kidney Transplantation/methods*
Male
Prevalence
Renal Insufficiency/therapy
Retrospective Studies
Risk Factors
Sirolimus/pharmacology
Steroids/therapeutic use

Keywords

cholesterol; triglycerides; docosahexaenoic acid; eicosapentaenoic acid; sirolimus

한글 키워드

콜레스테롤; 트리글리세라이드; 도코사헥사엔산; 에이코사펜타엔산; 시롤리무스

KMCRIC summary and commentary

없음

Korean Study

Abstract

Life expectancy after pediatric renal transplantation remains lower than that of the normal population largely due to cardiovascular morbidity and mortality. Hyperlipidemia is a potentially modifiable risk factor for cardiovascular morbidity. Retrospective chart review of all available pediatric renal transplant patients (26) in a single center with assessment of anthropometry, renal function, steroid, calcineurin or mTOR inhibitor exposure and Ω3 FA supplementation. Eighteen transplant recipients without Ω3 FA supplementation served as control. Nutrition and supplement surveys were conducted with standardized questionnaires. Fasting cholesterol values were compared using the latest value prior to start of Ω3 FA and at last follow-up. Eight patients (five receiving mTOR inhibitor) started Ω3 FA supplementation at a mean dose of 29.2 ± 12 mg of EPA/kg and 16.1 ± 7.4 mg DHA/kg body weight. Median duration of treatment was 2.5 yr (range 0.8-5.9 yr) and their total fasting cholesterol at last follow-up dropped significantly from 5.08 ± 0.97 (control group 3.77 ± 0.81, p = 0.0084) to 4.17 ± 0.54 mm (p = 0.0158). High-density lipoprotein cholesterol increased not significantly from 1.74 ± 0.49 to 2.02 ± 0.93 mm. No patient had increased bleeding. Supplementation of omega-3 FAs may reduce hyperlipidaemia after pediatric renal transplantation.

국문초록

Language

영어

첨부파일